CINCINNATI--(BUSINESS WIRE)--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company’s fiscal 2011 sales and earnings estimates. Based on the Company’s business planning and budgeting activities for the fiscal year ending September 30, 2011, management expects net sales to be in the range of $165 to $170 million and per share diluted earnings to be between $0.77 and $0.82. The per share estimates assume an increase in average shares outstanding from approximately 41.2 million at fiscal 2010 year end to 41.3 million at fiscal 2011 year end. Net income is expected to increase between 15% and 20% from fiscal 2010 to fiscal 2011, excluding Bioline acquisition costs in 2010. The sales and earnings guidance provided in this press release is from expected internal growth and does not include the impact of any additional acquisitions the Company might complete during fiscal 2011.
